前电影制片厂高管杰伊·威廉斯在确诊晚期胰脏癌且经历多次化疗无效后，透过特殊管道获得了 Revolution Medicines 公司研发的新药 daraxonrasib。这款刚刚获得美国监管机构批准的标靶药物，在后期临床试验中将晚期患者的存活期几乎延长了一倍，为这个长期以来最难治疗的癌症领域带来了重大突破。

这款名为 Rasonque 的新药采用了创新的「分子胶」机制，能够标靶过去被认为无法对付的 KRAS 基因突变，透过将致病蛋白与健康蛋白结合来使其失去活性。随著这项技术的成功，各大药厂纷纷投入胰脏癌药物研发，预计到 2035 年全球胰脏癌药物市场将从目前的不到 5 亿美元飙升至 120 亿美元，而 daraxonrasib 单一药物的年销售额就有望突破 90 亿美元。

尽管 Revolution Medicines 目前在市场上处于领先地位，并已开始将试验扩展至早期胰脏癌及肺癌患者，但由于患者最终可能会对药物产生抗药性，研究人员正积极寻求联合治疗方案。例如将 daraxonrasib 与其他标靶药物结合使用，已在初期试验中展现出更佳的肿瘤缩小效果，为患者争取更多时间等待更有效的疗法问世。

Jay Williams, a former movie studio executive who was diagnosed with advanced pancreatic cancer and exhausted traditional chemotherapy options, gained early access to a new drug called daraxonrasib developed by Revolution Medicines. This targeted medication, which recently secured US regulatory approval, nearly doubled the survival time for advanced patients in final-stage trials, marking a significant breakthrough for one of the most notoriously difficult cancers to treat.

Marketed under the brand name Rasonque, the drug utilizes an innovative "molecular glue" mechanism to target the KRAS gene mutation—previously considered undruggable—by cementing the disease-causing protein to a healthy one to inactivate it. Following this technological validation, pharmaceutical companies are rapidly accelerating pancreatic cancer drug development, with the global market projected to skyrocket from under $500 million today to $12 billion by 2035, while daraxonrasib alone could generate over $9 billion in annual sales.

Although Revolution Medicines currently leads the race and is expanding trials to include early-stage pancreatic cancer and lung cancer patients, researchers are urgently exploring combination therapies to combat eventual drug resistance. Early trials combining daraxonrasib with other targeted medications have already demonstrated superior tumor-shrinking results, offering patients renewed optimism and potentially buying them crucial time for even more advanced treatments to emerge.